Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019 | Zendy

Allison W. Kurian | Zendy; Kevin C. Ward | Zendy; Paul Abrahamse | Zendy; Irina Bondarenko | Zendy; Ann S. Hamilton | Zendy; Dennis Deapen | Zendy; Monica Morrow | Zendy; Jonathan S. Berek | Zendy; Timothy P. Hofer | Zendy; Steven J. Katz | Zendy

Open Access

Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019

Author(s) -

Allison W. Kurian,

Kevin C. Ward,

Paul Abrahamse,

Irina Bondarenko,

Ann S. Hamilton,

Dennis Deapen,

Monica Morrow,

Jonathan S. Berek,

Timothy P. Hofer,

Steven J. Katz

Publication year - 2021

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.20.02785

Subject(s) - medicine , chek2 , ovarian cancer , breast cancer , mutyh , msh6 , msh2 , palb2 , genetic testing , oncology , cancer , germline mutation , cancer research , colorectal cancer , dna mismatch repair , genetics , biology , mutation , gene

Genetic testing is important for breast and ovarian cancer risk reduction and treatment, yet little is known about its evolving use.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Address

About

Learn

Download the Zendy App

Discover

Explore